Category Archives: Global News Feed

SOUTH SAN FRANCISCO, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical?stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, today announced that members of its senior management team will participate in the virtual BofA Securities 2022 Biotech SMID Cap Conference on Thursday, Dec. 8 at 1:40 pm ET.

Read more here:
Lyell Immunopharma to Participate in BofA Securities Biotech Conference

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) --  Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, will host a live webcast to review the Company’s clinical data on the AMELI-01 study (evaluating UCART123) presented at the ASH Annual Meeting, and provide a Company update, on December 13, 2022.

Originally posted here:
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022

REYKJAVIK, Iceland, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced changes to its leadership team. Mark Levick, Chief Executive Officer has decided to step down and Robert Wessman, Executive Chairman and founder will become CEO, leading the next phase of growth. Hafrun Fridriksdottir, previously Executive Vice President and Head of Global R&D at Teva, has been appointed Chief Operating Officer. Changes to the leadership team are effective January 1, 2023.

Read this article:
Alvotech Announces Changes to its Leadership Team

NEW YORK, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the Biologics License Application (“BLA”) for the investigational medicine 131I-omburtamab (“omburtamab”) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma.

Excerpt from:
Y-mAbs Announces Complete Response Letter for Omburtamab Biologics License Application

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021.

View original post here:
Theratechnologies Announces Update from Ongoing TH1902 Study

SAN DIEGO, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that Jeff Stein, Ph.D., President and CEO, will participate in a panel discussion at the World Antiviral Congress being held in San Diego, California from November 28-December 1, 2022.

Read the rest here:
Cidara Therapeutics to Participate in the World Antiviral Congress 2022

ANDOVER, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming investor conferences:

Read the rest here:
Oncorus to Participate in Upcoming Investor Conferences

VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced the initiation of clinical batches of production of its novel psychedelic-derived drug candidate, the MEAI- based molecule- CMND-100.

Continued here:
Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial

-- Business combination transaction with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, completed on November 22, 2022 ---- Closed concurrent, oversubscribed and upsized approximately $235 million private investment in public equity (“PIPE”), led by Frazier Healthcare Partners and Bain Capital Life Sciences --

See original here:
NewAmsterdam Pharma Debuts as Publicly Traded Company Focused on Developing Obicetrapib, a Low-Dose, Once-Daily Oral LDL-Lowering Agent with Promising...

NEWARK, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.

See the original post:
Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium